News
The delays, first revealed in Regeronās Q2 report, were chalked up to manufacturing issues at Novo Nordisk-owned plants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results